Drug Profile
Enoblituzumab companion diagnostic - ImaginAb
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator ImaginAb
- Developer ImaginAb Inc
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Diagnosis) in USA (Parenteral)
- 05 Sep 2012 Clinical trials in Cancer (diagnosis) in USA (Parenteral)